Ms. Han Thi Khanh Vinh, Member of the Board of Directors and CEO of Vietnam Pharmaceutical Corporation, delivers a speech at the Vietnam-France Business Forum.
At the Vietnam-France Business Forum held in Paris on June 11, 2025, witnessed by Prime Minister Pham Minh Chinh, high-ranking delegates from Vietnam, and numerous leaders of Vietnamese and French businesses, Vietnam Pharmaceutical Corporation JSC (Vinapharm) and Opella Group (Opella) signed an agreement recognizing Vinapharm’s increased ownership in Sanofi Vietnam JSC (Sanofi Vietnam) to 30%.
Prime Minister Pham Minh Chinh takes a commemorative photo with representatives of Vinapharm and Opella.
Ms. Han Thi Khanh Vinh, Member of the Board of Directors and CEO of Vinapharm, emphasized, “This agreement marks a significant milestone, affirming the comprehensive and long-term cooperation between the two sides. It is also a concrete and practical step by Vinapharm to contribute to realizing the orientation of strengthening cooperation with multinational pharmaceutical corporations, in line with the direction and guidance of the Prime Minister of Vietnam.”
Opella is the third-largest group in the world in the field of over-the-counter drugs, vitamins, minerals, and dietary supplements. The group owns 100 trusted global brands, a workforce of 11,000 people, 13 modern factories, and 4 research and development (R&D) centers, one of which is located in Ho Chi Minh City’s High-Tech Park, demonstrating Opella’s strong commitment to the Vietnamese market.
Vinapharm’s increased ownership in Sanofi Vietnam not only strengthens the strategic cooperation between the two sides but also contributes to the development of Vietnam’s healthcare industry towards modernity and sustainability.
Ceremony for the signing of the agreement recognizing the increased ownership of Vietnam Pharmaceutical Corporation JSC in Sanofi Vietnam JSC to 30%.
On the same day, Ms. Han Thi Khanh Vinh and Mr. Rafik Amrane, Vice President of Manufacturing and Supply and Member of the Executive Committee of Opella, had an audience with Prime Minister Pham Minh Chinh.
At the meeting, the Prime Minister affirmed that Vietnam is promoting the simplification of administrative procedures, especially in the fields of medicine and pharmaceuticals, while enhancing the efficiency of drug and dietary supplement quality management to protect the legitimate rights and interests of businesses and consumers.
The Prime Minister expressed his hope that the Opella Group will continue to expand its investment in research and production in Vietnam to better serve the consumption needs of Vietnamese people and those in the region, making a practical contribution to the care and improvement of community health.
Speaking at the meeting, Opella’s leader affirmed that, as the center of Southeast Asia, Vietnam remains one of Opella Group’s strategic markets. The factory in Vietnam will not only produce products for the Vietnamese market but also for export to other Southeast Asian and Asian countries.
At the same time, Opella committed to promoting technology transfer and supporting the improvement of domestic production capacity, thereby contributing to the development of Vietnam’s healthcare industry towards modernity, sustainability, and international integration.
Opella’s leadership also emphasized the long-term commitment of Opella and Vinapharm to accompany the Government and the Ministry of Health of Vietnam in providing innovative, safe, high-quality, and science-based healthcare products and solutions to enhance the health and happiness of the Vietnamese people.
“Optimizing Resources: The Strategic Approach to Managing 108 Surplus Offices in Bac Giang”
The province of Bac Giang will retain 136 offices for its new administrative units, out of a total of 244 offices that are subject to rearrangement. This leaves 108 surplus offices that require appropriate disposal.
“Why Do Americans and the Japanese Have Better Access to New Medications Than the Vietnamese? FPT Chairman Truong Gia Binh Questions the Disparity in Healthcare.”
“In the past decade, 460 new drugs have been introduced globally, yet only 9% of Vietnamese citizens have had access to these innovations, compared to 51% in Japan. This striking disparity prompts the question: how can we ensure that Vietnamese people have access to the same level of healthcare and pharmaceuticals as those in developed countries?”
Empowering Individuals with Health Knowledge: Long Chau Pharmacy Joins Hands with the Community to Enhance Early Disease Prevention Awareness
At the “Healthcare Innovation Forum 2025”, FPT Long Chau portrayed itself as a community-oriented pharmacy that understands the industry and is committed to contributing to the nation’s healthcare digital transformation. With technology, data, and dedication as its driving forces, FPT Long Chau is taking strides towards revolutionizing healthcare in Vietnam.
“Vietnam: The Next Global Hub for Clinical Trials?”
To realize grand dreams in healthcare, FPT Chairman Truong Gia Binh emphasizes the necessity of focusing on three key pillars: mechanism, innovation, and public-private collaboration.
Unveiling the Dark Side of Ho Chi Minh City’s Pharmaceutical Trade: Unlicensed Medicines Flood the Market
For the past two weeks, Ho Chi Minh City’s health authorities have been cracking down on illegal operations, uncovering 18 establishments dealing in untraceable medications and improperly manufactured cosmetics.
